[minti_button link="https://biocopy.ch/wp-content/uploads/2021/02/Forbes_Spin-offs-to-watch-2021.pdf" target="_blank"... read more →
BioCopy and CureVac present their contribution to the Covid-19 pandemic to representatives of the European Parliament and the European Commission at a virtual conference held by the... read more →
The St. Galler Tagblatt addresses the corona pandemic and clearly shows where there are still gaps in pandemic control and defence, but also reveals who can help find... read more →
In recent weeks, the BioCopy team has been working hard and applying BioCopy technology to help fight the global Sars Cov2 pandemic. The first promising partial results from a... read more →
As predicted by BioCopy in spring 2019, the current development of vaccines is too slow for the spread of a novel virus. COVID-19, respectively its pathogen Sars-Cov2, shows us... read more →
A few weeks after the first occurrence of the previously unknown corona virus (nCoV-2019), BioCopy held its 2nd Investors’ Symposium in Zurich on 23 January 2020. Around 50 interested... read more →
In mid-January 2020, BioCopy Holding AG was able to acquire the entire assets and patent portfolio of Biametrics GmbH. We have been working together with Biametrics GmbH for more... read more →